Career tips from our Global Head of HR
Sven Sommerlatte explains how important it is to reflect on the personal career strategy.
Search
Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
Smart scanners to spot fleas and ticks on your pet
How to identify fleas and ticks? With technology, vets can now spot pet parasites with high-definition videos in real time.
The Supplier Code of Conduct
BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
All hands-on deck to fight the ‘zombie’ rabies virus
We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
Data Privacy Statement
This privacy statement of Boehringer Ingelheim International GmbH (hereafter "Boehringer Ingelheim") describes what personal data are collected by this website and how these data are processed.
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Update Israel and Gaza conflict
Update on Israel and the Palestine territories
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
Daniel Kiesenhofer
Diverse, caring, collaborative - Daniel Kiesenhofer on Boehringer Ingelheim
Candice is moving to Germany
Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.